Here is the full statement by current CDC Senior Scientist on Vaccine-Autism questions: Dr. William Thompson. Stay tuned to this website for an update on the story, soon.
I regret that my [CDC] coauthors and I omitted statistically significant information in our 2004 article published in the Journal of Pediatrics.
My primary job duties while working in the immunization safety branch from 2000 to 2006 were to lead or colead three major vaccine safety studies. The MADDSP MMR-Autism Cases
Control Study was being carried out in response to the Wakefield Lancet study that suggested an association between the MMR vaccine and an autism-like health outcome.
There were several major concerns among scientists and consumer advocates outside the CDC in the fall of 2000 regarding the execution of the Verstraeten study.
One of the important goals that was determined upfront in the spring of 2001 before any of these studies started was to have all three protocols vetted outside the CDC prior to the start of the analyses so that consumer advocates could not claim that we were presenting analyses that suited our own goals and biases.
We hypothesized that if we found statistically significant effects at either 18- or 36-month thresholds, we would conclude that vaccinating children early with MMR vaccine could lead to autism-like characteristics or features.
We all met and finalized the study protocol and analysis plan. The goal was to not deviate from the analysis plan to avoid the debacle that occurred with the Verstraeten Thimerosal study published in Pediatrics in 2003.
At the September 5 meeting, we discussed in detail how to code race for both the sample and the birth certificate sample. At the bottom of table 7, it also shows that for the
nonbirth certificate sample, the adjusted race effect statistical significance was huge.
All the authors and I met and decided sometime between August and September 2002 not to report any race effects for the paper. Sometime soon after the meeting, where we decided to exclude reporting any race effects, the coauthors scheduled a meeting to destroy documents related to the study.
The remaining four coauthors all met and brought a big garbage can into the meeting room and reviewed and went through all the hard copy documents that we had thought we should discard and put them in a huge garbage can.
However, because I assumed it was illegal and would violate both FOIA and DOJ requests, I kept hard copies of all documents in my office, and I retained all associated computer files.
The Biden administration quietly ended President Donald Trump’s policy that saw many Americans receive lower cost insulin and epinephrine pens on the same day he promised to purchase 500 million COVID-19 vaccines to be sent to foreign countries.
Yesterday, Biden promised world leaders at the G7 summit that the United States of America would finance the purchase of 500 million COVID-19 vaccines to be given to poor countries at almost precisely the same time the White House budget office approved Biden’s plan to slash a Trump-era program that provided low cost insulin and epinephrine pens to low income Americans.
On the ending of the Trump-era program, Fox Business reported, “The measure, signed off on under the previous administration in December, aimed to require some 340B community health centers to deliver savings to low-income patients for insulin and epinephrine in a bid to bring down unaffordable prices.” Fox Business notes that the Biden administration refused to offer a comment when asked by the cable network.
Hours earlier, Biden promised to unveil an American-led worldwide program to address COVID-19 vaccines as he prepared to leave the United States for the United Kingdom to meet with world leaders. After arriving, and only an hour before the White House budget office would make its announcement regarding insulin and epinephrine pens, the Washington Post revealed the administration’s plan to buy 500 million Pfizer vaccines, and reported that “President Biden is slated to announce the plan this week at the Group of Seven meeting in Britain, where he is expected to be joined by Pfizer CEO Albert Bourla.”
This happened earlier today, with Biden appearing before the international media to make the announcement. Today we’re taking a major step that will super charge the fight against the global pandemic. “At my direction, the United states will purchase an additional half billion doses from Pfizer, Pfizer vaccine, that will donate nearly 100 low and lower middle income countries, they will be the beneficiaries. Let me say that again, the United States will purchase a half a billion doses of Pfizer’s COVID-19 vaccine to donate to nearly 100 nations that are in dire need in the fight against this pandemic.”
The development and rollout of COVID-19 vaccines has minted at least nine new billionaires in the pharma industry, whose new combined wealth is enough to buy shots for a staggering 780 million people in low-income nations.
Nine executives from Moderna, BioNTech, ROVI and CanSino Biologics have hugely profited from the pandemic that has so far killed 3.4 million people worldwide, as their individual wealth soared past the billion-dollar mark over the last year.
The rich list was compiled by the People’s Vaccine Alliance, a campaign group that includes Oxfam, UNAIDS, Global Justice Now and Amnesty International, using the Forbes Rich List.